AstraZeneca net climbs 31%, helped by strong sales of Crestor
Article Abstract:
AstraZeneca PLC of the United Kingdom posted a second quarter soaring net profit increase of 31 percent to $1.6 billion, up from $1.22 billion last year. Revenues were buoyed by sales of top pharmaceuticals, particularly breast cancer drug Arimidex and Cholesterol drug Crestor.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Autonomy is facing an uncertain forecast
Article Abstract:
Autonomy Corp. expects to reach analysts' earnings forecasts for the 2001 second-quarter. However, the company is continuing to see contract deferrals which may affect its results after the second-quarter.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
Biodata cuts forecasts
Article Abstract:
Biodata Information Technology AG is forecasting a major decline in its sales and earnings for the 2001 third-quarter and full-year. The company blamed the forecast on the global economic slowdown.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: AstraZeneca gets close to end of auction of unit. Novartis AG emerges as suitor for Monsanto. Abbott Will Acquire BASF's Knoll Unit
- Abstracts: Beijing: bright lights, big city. Maintaining a sense of history. Work smarter, not harder and learn to say no
- Abstracts: More declines in chip sales. Intel offers chip set earlier
- Abstracts: Analysts feel the heat. Asia ties prosperity to IT
- Abstracts: Ericsson revamps management amid intensified competition. Telia seeks to buy SBC's 41.6% stake in TeleDanmark